In comments on the Centers for Medicare & Medicaid Services' advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs, AHA commends the agency's willingness to address excessive growth in drug prices, but "given the amount of model specifics still to be determined, the anticipated operational burdens, as well as other logistical concerns, the AHA urges CMS to consider narrowing the scope of the program to a more targeted intervention than that described in the ANPRM." AHA's Dec. 27 comments and concerns focused on the ANPRM's impact on hospitals participating in the 340B Drug Pricing Program; regulatory and operational burden; payment reductions; and model vendors' fees and policies. The AHA noted that its primary concern is the model's interaction with the 340B program and asked CMS to hold 340B hospitals harmless under the model. AHA said it looks forward to working with CMS "to improve the IPI model."
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.
AHA Releases New Report that Shows Continued Rising Drug Prices and Drug Shortages are Disrupting Patient Care, Hospital Budgets
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Insights and Analysis
Also in this weekly roundup of health news: AHA president and CEO Rick Pollack speaks to HealthLeaders about the association’s year ahead; digital health…
As Congress prioritizes action to lower drug prices, the Campaign for Sustainable Rx Pricing yesterday announced a website to help lawmakers and their staff…
The AHA today voiced support for a Centers for Medicare…